OncLive® On Air
By OncLive® On Air
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by OncLive® On Air
Category: Health & Fitness
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 3
Reviews: 0
Episodes: 500
Description
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
| Episode | Date |
|---|---|
|
S13 Ep35: Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD
|
Jul 24, 2025 |
|
S13 Ep34: Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD
|
Jul 23, 2025 |
|
S13 Ep33: Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC
|
Jul 21, 2025 |
|
S13 Ep32: European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD
|
Jul 17, 2025 |
|
S13 Ep31: IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD
|
Jul 16, 2025 |
|
S13 Ep30: Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ
|
Jul 15, 2025 |
|
S13 Ep29: FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP
|
Jul 14, 2025 |
|
S13 Ep28: Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD
|
Jul 10, 2025 |
|
S13 Ep26: ASCO 2025 Plenary — MATTERHORN
|
Jul 07, 2025 |
|
S13 Ep25: FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
|
Jul 03, 2025 |
|
S13 Ep24: Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD
|
Jul 02, 2025 |
|
S13 Ep23: IMA203 emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD
|
Jun 30, 2025 |
|
S13 Ep22: BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD
|
Jun 26, 2025 |
|
S13 Ep21: T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD
|
Jun 25, 2025 |
|
S13 Ep20: ASCO 2025 Plenary: SERENA-6
|
Jun 24, 2025 |
|
S13 Ep19: Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD
|
Jun 23, 2025 |
|
S13 Ep18: Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD
|
Jun 19, 2025 |
|
S13 Ep17: 42nd Annual Miami Breast Cancer Conference® Podcast: OncLive On Air CE, Powered by PER
|
Jun 18, 2025 |
|
S13 Ep16: Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS
|
Jun 17, 2025 |
|
S13 Ep15: The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
|
Jun 16, 2025 |
|
S13 Ep14: Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD
|
Jun 12, 2025 |
|
S13 Ep13: T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD
|
Jun 11, 2025 |
|
S13 Ep12: Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD
|
Jun 10, 2025 |
|
S13 Ep11: Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM
|
Jun 09, 2025 |
|
S13 Ep10: Updates and Innovations in Non-Opioid Pain Management Strategies for Breast Cancer Patients Post-Surgical Intervention
|
Jun 04, 2025 |
|
S13 Ep9: Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM
|
Jun 02, 2025 |
|
S13 Ep8: Oncology PER® Spectives: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
|
Jun 02, 2025 |
|
S13 Ep7: Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD
|
May 29, 2025 |
|
S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD
|
May 28, 2025 |
|
S13 Ep5: Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD
|
May 26, 2025 |
|
S13 Ep4: Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD
|
May 22, 2025 |
|
S13 Ep3: Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD
|
May 19, 2025 |
|
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer
|
May 19, 2025 |
|
S13 Ep1: Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott
|
May 15, 2025 |
|
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2
|
May 14, 2025 |
|
S12 Ep49: MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD
|
May 12, 2025 |
|
S12 Ep48: Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation
|
May 12, 2025 |
|
S12 Ep47: Early-Phase RAS Inhibitor Research Sparks Interest in NSCLC: With Kathryn C. Arbour, MD
|
May 08, 2025 |
|
S12 Ep46: Managing Side Effects and Fertility for Premenopausal Patients with Advanced HR+ Breast Cancer
|
May 07, 2025 |
|
S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA
|
May 05, 2025 |
|
S12 Ep44: Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH
|
May 01, 2025 |
|
S12 Ep43: Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD
|
Apr 28, 2025 |
|
S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD
|
Apr 24, 2025 |
|
S12 Ep41: Oncodetect MRD Detection Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD
|
Apr 23, 2025 |
|
S12 Ep40: Motivation and Consistency Are Key to Building a Successful Oncology Educational Platform: With Chandler Park, MD; and Paul Hanona, MD
|
Apr 21, 2025 |
|
S12 Ep39: Social Media Unlocks New Avenues for Expanding Access to Oncology Education: With Chandler Park, MD; and Paul Hanona, MD
|
Apr 16, 2025 |
|
S12 Ep38: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC
|
Apr 16, 2025 |
|
S12 Ep37: Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD
|
Apr 14, 2025 |
|
S12 Ep36: Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD
|
Apr 10, 2025 |
|
S12 Ep35: Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD
|
Apr 09, 2025 |
|
S12 Ep34: AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS
|
Apr 07, 2025 |
|
S12 Ep33: Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD
|
Apr 03, 2025 |
|
S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD
|
Apr 03, 2025 |
|
S12 Ep31: Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD
|
Mar 31, 2025 |
|
S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD
|
Mar 27, 2025 |
|
S12 Ep29: Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc
|
Mar 26, 2025 |
|
S12 Ep28: Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD
|
Mar 24, 2025 |
|
S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
|
Mar 20, 2025 |
|
S12 Ep27: Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD
|
Mar 17, 2025 |
|
S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD
|
Mar 13, 2025 |
|
S12 Ep25: Perioperative Durvalumab Improves Survival in MIBC: Navigating the NIAGARA Trial Findings With: Chandler Park, MD; and Petros Grivas, MD, PhD
|
Mar 12, 2025 |
|
S12 Ep24: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
|
Mar 11, 2025 |
|
S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc
|
Mar 10, 2025 |
|
S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD
|
Mar 06, 2025 |
|
S12 Ep21: Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma
|
Mar 04, 2025 |
|
S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD
|
Mar 03, 2025 |
|
S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
|
Feb 27, 2025 |
|
S12 Ep18: Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD
|
Feb 26, 2025 |
|
S12 Ep17: Triplet Chemo Trial Raises Importance of Accurately Defined Subgroups in Biliary Tract Cancer Research: With Rachna Shroff, MD, MS, FASCO
|
Feb 24, 2025 |
|
S12 Ep16: DA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD
|
Feb 20, 2025 |
|
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
|
Feb 17, 2025 |
|
S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
|
Feb 13, 2025 |
|
S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
|
Feb 10, 2025 |
|
S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD
|
Feb 06, 2025 |
|
S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
|
Feb 03, 2025 |
|
S12 Ep9: How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD
|
Jan 30, 2025 |
|
S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
|
Jan 28, 2025 |
|
S12 Ep7: Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
|
Jan 23, 2025 |
|
S12 Ep6: FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
|
Jan 20, 2025 |
|
S12 Ep5: MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
|
Jan 15, 2025 |
|
S12 Ep4: Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
|
Jan 13, 2025 |
|
S12 Ep3: Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
|
Jan 08, 2025 |
|
S12 Ep2: Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD
|
Jan 07, 2025 |
|
S12 Ep1: FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD
|
Jan 02, 2025 |
|
S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
|
Jan 01, 2025 |
|
S11 Ep49: Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
|
Dec 31, 2024 |
|
S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
|
Dec 30, 2024 |
|
S11 Ep47: Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes
|
Dec 24, 2024 |
|
S11 Ep46: The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
|
Dec 24, 2024 |
|
S11 Ep45: Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
|
Dec 23, 2024 |
|
S11 Ep44: Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD
|
Dec 23, 2024 |
|
S11 Ep43: Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
|
Dec 19, 2024 |
|
S11 Ep41: Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
|
Dec 18, 2024 |
|
S11 Ep42: Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS
|
Dec 16, 2024 |
|
S11 Ep41: Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD
|
Dec 13, 2024 |
|
S11 Ep41: Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
|
Dec 12, 2024 |
|
S11 Ep40: T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD
|
Dec 10, 2024 |
|
S11 Ep40: How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD
|
Dec 06, 2024 |
|
S11 Ep38: Pancreatic Cancer Research Surfaces Treatment Developments and Challenges: With John Strickler, MD
|
Dec 02, 2024 |
|
S11 Ep38: FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
|
Nov 28, 2024 |
|
S11 Ep39: Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
|
Nov 27, 2024 |
|
S11 Ep38: Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
|
Nov 25, 2024 |
|
S11 Ep37: Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH
|
Nov 21, 2024 |
|
S11 Ep36: HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
|
Nov 18, 2024 |
|
S11 Ep35: FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
|
Nov 14, 2024 |
|
S11 Ep34: Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS
|
Nov 11, 2024 |
|
S11 Ep33: Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS
|
Nov 07, 2024 |
|
S11 Ep32: Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
|
Nov 06, 2024 |
|
S11 Ep31: How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd
|
Nov 04, 2024 |
|
S11 Ep30: SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD
|
Oct 31, 2024 |
|
S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
|
Oct 30, 2024 |
|
S11 Ep28: Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD
|
Oct 28, 2024 |
|
S11 Ep27: Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
|
Oct 24, 2024 |
|
S11 Ep26: Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH
|
Oct 21, 2024 |
|
S11 Ep25: FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL
|
Oct 17, 2024 |
|
S11 Ep24: How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
|
Oct 16, 2024 |
|
S11 Ep23: Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
|
Oct 14, 2024 |
|
S11 Ep22: FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
|
Oct 10, 2024 |
|
S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
|
Oct 07, 2024 |
|
S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC
|
Oct 03, 2024 |
|
S11 Ep19: Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD
|
Oct 02, 2024 |
|
S11 Ep18: Board Review Resources 2024
|
Sep 30, 2024 |
|
S11 Ep17: How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
|
Sep 26, 2024 |
|
S11 Ep16: FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma
|
Sep 23, 2024 |
|
S11 Ep15: Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting
|
Sep 19, 2024 |
|
S11 Ep14: Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024
|
Sep 18, 2024 |
|
S11 Ep13: FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma
|
Sep 16, 2024 |
|
S11 Ep12: Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
|
Sep 11, 2024 |
|
S11 Ep11: Heme & Onc Fellow Board Review Tips 2024
|
Sep 09, 2024 |
|
S11 Ep10: Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions
|
Sep 05, 2024 |
|
S11 Ep9: Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
|
Sep 04, 2024 |
|
S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
|
Sep 02, 2024 |
|
S11 Ep7: Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management
|
Aug 29, 2024 |
|
S11 Ep6: FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer
|
Aug 26, 2024 |
|
S11 Ep5: Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
|
Aug 22, 2024 |
|
S11 Ep4: Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
|
Aug 21, 2024 |
|
S11 Ep3: Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond
|
Aug 19, 2024 |
|
S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
|
Aug 15, 2024 |
|
S11 Ep2: ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
|
Aug 12, 2024 |
|
S11 Ep1: Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC
|
Aug 08, 2024 |
|
S10 Ep50: Park and Grivas Expand on Treatment Updates in Bladder Cancer
|
Aug 07, 2024 |
|
S10 Ep49: Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC
|
Aug 05, 2024 |
|
S10 Ep48: Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC
|
Aug 01, 2024 |
|
S10 Ep47: Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer
|
Jul 29, 2024 |
|
S10 Ep47: Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer
|
Jul 25, 2024 |
|
S10 Ep46: Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer
|
Jul 24, 2024 |
|
S10 Ep45: Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
|
Jul 18, 2024 |
|
S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
|
Jul 15, 2024 |
|
S10 Ep43: Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
|
Jul 11, 2024 |
|
S10 Ep42: Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer
|
Jul 10, 2024 |
|
S10 Ep41: ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer
|
Jul 08, 2024 |
|
S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia
|
Jul 01, 2024 |
|
S10 Ep39: Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing
|
Jun 27, 2024 |
|
S10 Ep38: Agulnik Highlights Key Updates in GIST Research and Management
|
Jun 24, 2024 |
|
S10 Ep37: Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs
|
Jun 20, 2024 |
|
S10 Ep36: Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma
|
Jun 17, 2024 |
|
S10 Ep35: ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
|
Jun 10, 2024 |
|
S10 Ep35: Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
|
Jun 06, 2024 |
|
S10 Ep34: Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
|
Jun 03, 2024 |
|
S10 Ep33: Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
|
May 30, 2024 |
|
S10 Ep33: Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
|
May 30, 2024 |
|
S10 Ep32: Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
|
May 23, 2024 |
|
S10 Ep31: Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa
|
May 20, 2024 |
|
S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
|
May 13, 2024 |
|
S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
|
May 09, 2024 |
|
S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
|
May 06, 2024 |
|
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
|
May 02, 2024 |
|
S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
|
Apr 29, 2024 |
|
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
|
Apr 22, 2024 |
|
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
|
Apr 18, 2024 |
|
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
|
Apr 11, 2024 |
|
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
|
Apr 08, 2024 |
|
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
|
Apr 01, 2024 |
|
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
|
Mar 28, 2024 |
|
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
|
Mar 25, 2024 |
|
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
|
Mar 21, 2024 |
|
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
|
Mar 18, 2024 |
|
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
|
Mar 11, 2024 |
|
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
|
Mar 07, 2024 |
|
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
|
Feb 29, 2024 |
|
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
|
Feb 26, 2024 |
|
S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference
|
Feb 22, 2024 |
|
S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness
|
Feb 19, 2024 |
|
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
|
Feb 12, 2024 |
|
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
|
Feb 08, 2024 |
|
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
|
Feb 05, 2024 |
|
S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
|
Jan 29, 2024 |
|
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
|
Jan 25, 2024 |
|
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
|
Jan 22, 2024 |
|
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
|
Jan 15, 2024 |
|
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
|
Jan 11, 2024 |
|
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
|
Jan 08, 2024 |
|
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
|
Jan 04, 2024 |
|
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
|
Jan 01, 2024 |
|
S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
|
Dec 28, 2023 |
|
S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
|
Dec 25, 2023 |
|
S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
|
Dec 21, 2023 |
|
S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
|
Dec 18, 2023 |
|
S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
|
Dec 11, 2023 |
|
S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
|
Dec 07, 2023 |
|
S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Dec 04, 2023 |
|
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
|
Nov 30, 2023 |
|
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
|
Nov 23, 2023 |
|
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
|
Nov 20, 2023 |
|
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
|
Nov 16, 2023 |
|
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
|
Nov 13, 2023 |
|
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
|
Nov 09, 2023 |
|
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
|
Nov 06, 2023 |
|
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
|
Oct 30, 2023 |
|
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
|
Oct 26, 2023 |
|
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
|
Oct 23, 2023 |
|
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
|
Oct 19, 2023 |
|
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
|
Oct 16, 2023 |
|
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
|
Oct 12, 2023 |
|
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
|
Oct 09, 2023 |
|
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
|
Oct 05, 2023 |
|
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
|
Oct 02, 2023 |
|
S9 Ep29: Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS
|
Sep 28, 2023 |
|
S9 Ep28: FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
|
Sep 21, 2023 |
|
S9 Ep27: Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST
|
Sep 18, 2023 |
|
S9 Ep26: Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer
|
Sep 14, 2023 |
|
S9 Ep25: Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities
|
Sep 11, 2023 |
|
S9 Ep24: FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma
|
Sep 07, 2023 |
|
S9 Ep23: Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
|
Sep 04, 2023 |
|
S9 Ep22: Kelley Discusses Efficacy and Safety Considerations With the STRIDE Regimen in HCC
|
Aug 31, 2023 |
|
S9 Ep21: FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
|
Aug 28, 2023 |
|
S9 Ep20: FDA Approval Insights: Quizartinib in Newly Diagnosed, FLT3-ITD+ AML
|
Aug 21, 2023 |
|
S9 Ep19: Trent Breaks Down Mutation Testing and ctDNA Monitoring in GIST
|
Aug 17, 2023 |
|
S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
|
Aug 14, 2023 |
|
S9 Ep17: Sanai Spotlights Meningioma Symptoms, Treatment Options, and Research Needs
|
Aug 10, 2023 |
|
S9 Ep16: Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
|
Aug 07, 2023 |
|
S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
Aug 03, 2023 |
|
S9 Ep14: Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST
|
Jul 31, 2023 |
|
S9 Ep13: Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL
|
Jul 24, 2023 |
|
S9 Ep12: Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer
|
Jul 20, 2023 |
|
S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
|
Jul 17, 2023 |
|
S9 Ep10: Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management
|
Jul 13, 2023 |
|
S9 Ep9: FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis
|
Jul 10, 2023 |
|
S9 Ep8: King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer
|
Jul 06, 2023 |
|
S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
|
Jul 03, 2023 |
|
S9 Ep6: Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023
|
Jun 29, 2023 |
|
S9 Ep5: Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care
|
Jun 22, 2023 |
|
S9 Ep4: Reuss Reviews the Development of LP-300 in Advanced NSCLC
|
Jun 19, 2023 |
|
S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
|
Jun 15, 2023 |
|
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
|
Jun 12, 2023 |
|
S9 Ep1: Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
|
Jun 08, 2023 |
|
S8 Ep50: Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
|
Jun 05, 2023 |
|
S8 Ep49: Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
|
May 29, 2023 |
|
S8 Ep48: Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors
|
May 25, 2023 |
|
S8 Ep47: Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment
|
May 22, 2023 |
|
S8 Ep46: Oncology Professionals Explain the Nuances of Career-Building Mentorship and Self-Advocacy
|
May 18, 2023 |
|
S8 Ep45: FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant
|
May 15, 2023 |
|
S8 Ep44: Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate
|
May 11, 2023 |
|
S8 Ep43: Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors
|
May 08, 2023 |
|
S8 Ep41: Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials
|
May 01, 2023 |
|
S8 Ep40: Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer
|
Apr 27, 2023 |
|
S8 Ep39: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
|
Apr 24, 2023 |
|
S8 Ep38: Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer
|
Apr 20, 2023 |
|
S8 Ep37: Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
|
Apr 17, 2023 |
|
S8 Ep36: FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer
|
Apr 13, 2023 |
|
S8 Ep35: Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates
|
Apr 10, 2023 |
|
S8 Ep34: Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management
|
Apr 06, 2023 |
|
S8 Ep33: Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
|
Apr 03, 2023 |
|
S8 Ep32: FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
|
Mar 30, 2023 |
|
S8 Ep31: Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration
|
Mar 27, 2023 |
|
S8 Ep29: FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
|
Mar 20, 2023 |
|
S8 Ep28: Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC
|
Mar 16, 2023 |
|
S8 Ep27: Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients
|
Mar 13, 2023 |
|
S8 Ep26: FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
|
Mar 09, 2023 |
|
S8 Ep25: CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
|
Mar 06, 2023 |
|
S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma
|
Mar 02, 2023 |
|
S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL
|
Feb 27, 2023 |
|
S8 Ep22: Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
|
Feb 23, 2023 |
|
S8 Ep21: FDA Approval Insights: Zanubrutinib in CLL and SLL
|
Feb 16, 2023 |
|
S8 Ep20: Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies
|
Feb 13, 2023 |
|
S8 Ep19: D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
|
Feb 09, 2023 |
|
S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
|
Feb 06, 2023 |
|
S8 Ep18: Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
|
Feb 02, 2023 |
|
S8 Ep17: Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
|
Jan 30, 2023 |
|
S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
|
Jan 26, 2023 |
|
S8 Ep16: Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer
|
Jan 23, 2023 |
|
S8 Ep15: Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC
|
Jan 19, 2023 |
|
S8 Ep14: Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer
|
Jan 16, 2023 |
|
S8 Ep14: Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
|
Jan 12, 2023 |
|
S8 Ep12: Breast Cancer Experts Review HR+ Treatment Updates From SABCS 2022
|
Jan 05, 2023 |
|
S8 Ep11: Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates
|
Jan 02, 2023 |
|
S8 Ep10: Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
|
Dec 29, 2022 |
|
S8 Ep9: Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
|
Dec 26, 2022 |
|
S8 Ep8: Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment
|
Dec 22, 2022 |
|
S8 Ep7: Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
|
Dec 19, 2022 |
|
S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
|
Dec 15, 2022 |
|
S8 Ep5: Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
|
Dec 12, 2022 |
|
S8 Ep4: Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL
|
Dec 08, 2022 |
|
S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
|
Dec 05, 2022 |
|
S8 Ep2: Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer
|
Dec 01, 2022 |
|
S8 Ep1: Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship
|
Nov 28, 2022 |
|
S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
|
Nov 24, 2022 |
|
S7 Ep49: Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
|
Nov 21, 2022 |
|
S7 Ep48: Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
|
Nov 17, 2022 |
|
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
|
Nov 14, 2022 |
|
S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
|
Nov 10, 2022 |
|
S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
|
Nov 07, 2022 |
|
S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
|
Nov 03, 2022 |
|
S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
|
Oct 31, 2022 |
|
S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
|
Oct 27, 2022 |
|
S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
|
Oct 24, 2022 |
|
S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
|
Oct 20, 2022 |
|
S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
|
Oct 17, 2022 |
|
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
|
Oct 13, 2022 |
|
S7 Ep37: Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
|
Oct 10, 2022 |
|
S7 Ep36: Velcheti Discusses Mobile Telehealth-Based Research to Close Cancer Care Gaps
|
Oct 06, 2022 |
|
S7 Ep35: FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer
|
Oct 03, 2022 |
|
S7 Ep34: Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors
|
Sep 29, 2022 |
|
S7 Ep33: Deol on the Importance of a Well-Rounded Fellowship Experience
|
Sep 26, 2022 |
|
S7 Ep32: Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
|
Sep 22, 2022 |
|
S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
|
Sep 19, 2022 |
|
S7 Ep30: Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
|
Sep 15, 2022 |
|
S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC
|
Sep 12, 2022 |
|
S7 Ep28: Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
|
Sep 08, 2022 |
|
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
|
Sep 05, 2022 |
|
S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers
|
Sep 01, 2022 |
|
S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
|
Aug 29, 2022 |
|
S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
|
Aug 25, 2022 |
|
S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
|
Aug 22, 2022 |
|
S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
|
Aug 18, 2022 |
|
S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
|
Aug 15, 2022 |
|
S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
|
Aug 11, 2022 |
|
S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
|
Aug 08, 2022 |
|
S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
|
Aug 04, 2022 |
|
S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
|
Aug 01, 2022 |
|
S7 Ep18: FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
|
Jul 28, 2022 |
|
S7 Ep17: Wagner Weighs In On Research and Development in Angiosarcoma
|
Jul 25, 2022 |
|
S7 Ep16: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
|
Jul 21, 2022 |
|
S7 Ep15: Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
|
Jul 18, 2022 |
|
S7 Ep14: Jain Discusses the Driving Forces of Gender Inequities in Medicine
|
Jul 14, 2022 |
|
S7 Ep13: Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer
|
Jul 11, 2022 |
|
S7 Ep12: Research Reflections: Tarantino Talks Through the Implications of ASCO 2022 Data in Breast Cancer
|
Jul 07, 2022 |
|
S7 Ep11: Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)
|
Jul 04, 2022 |
|
S7 Ep10: Duma Discusses the Unique Challenges of Women With Lung Cancer
|
Jun 30, 2022 |
|
S7 Ep9: Leukemia Pioneers Chronicle Career Experiences and Milestones
|
Jun 27, 2022 |
|
S7 Ep8: Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer
|
Jun 23, 2022 |
|
S7 Ep7: Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
|
Jun 20, 2022 |
|
S7 Ep6: Lee Lays Out Treatment Developments in Non–Clear Cell RCC
|
Jun 16, 2022 |
|
S7 Ep5: Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC
|
Jun 13, 2022 |
|
S7 Ep4: Hua Highlights Innovative Research With Immunotherapy in NETs
|
Jun 09, 2022 |
|
S7 Ep3: Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
|
Jun 06, 2022 |
|
S7 Ep2: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
|
Jun 02, 2022 |
|
S7 Ep1: Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
|
May 30, 2022 |
|
S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer
|
May 26, 2022 |
|
S6 Ep49: Taylor Provides Insight Into Pirtobrutinib Resistance in CLL
|
May 23, 2022 |
|
S6 Ep48: Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma
|
May 19, 2022 |
|
S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC
|
May 16, 2022 |
|
S6 Ep46: Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer
|
May 12, 2022 |
|
S6 Ep45: Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC
|
May 09, 2022 |
|
S6 Ep44: Borgen Recommends Revamping Peer Review for a Post-COVID-19 World
|
May 05, 2022 |
|
S6 Ep43: FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
|
May 02, 2022 |
|
S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
|
Apr 28, 2022 |
|
S6 Ep41: Bardia Reflects on Important Data in HER2+ Breast Cancer
|
Apr 21, 2022 |
|
S6 Ep40: D'Abreo Addresses AEs in Metastatic Breast Cancer Care
|
Apr 14, 2022 |
|
S6 Ep39: Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis
|
Apr 07, 2022 |
|
S6 Ep38: FDA Approval Insights: Pacritinib in Myelofibrosis
|
Mar 31, 2022 |
|
S6 Ep37: Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022
|
Mar 24, 2022 |
|
S6 Ep36: Lyle and Patel Examine Diagnostic and Management Paradigms in MDS
|
Mar 17, 2022 |
|
S6 Ep35: Ross Reflects on Surgical Advances and Changing Trends in CRC
|
Mar 10, 2022 |
|
S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
|
Mar 03, 2022 |
|
S6 Ep34: Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer
|
Feb 24, 2022 |
|
S6 Ep28: Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
|
Feb 17, 2022 |
|
S6 Ep33: Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies
|
Feb 10, 2022 |
|
S6 Ep32: Simon Shares Steps Towards Bridging Clinical Trial Disparities in Cancer
|
Feb 07, 2022 |
|
S6 Ep31: Rare Cancers Report: Pediatric Neuroblastoma
|
Feb 03, 2022 |
|
S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia
|
Jan 31, 2022 |
|
S6 Ep29: Sorting Through Sexism, Guilt, and Motherhood in Medicine
|
Jan 27, 2022 |
|
S6 Ep27: Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management
|
Jan 20, 2022 |
|
S6 Ep26: Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL
|
Jan 17, 2022 |
|
S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology
|
Jan 13, 2022 |
|
S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
|
Jan 10, 2022 |
|
S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer
|
Jan 06, 2022 |
|
S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt
|
Jan 03, 2022 |
|
S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC
|
Dec 30, 2021 |
|
S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma
|
Dec 27, 2021 |
|
S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL
|
Dec 23, 2021 |
|
S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
|
Dec 20, 2021 |
|
S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers
|
Dec 16, 2021 |
|
S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
|
Dec 13, 2021 |
|
S6 Ep16: Coombs Previews Anticipated ASH Abstracts in CLL
|
Dec 09, 2021 |
|
S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC
|
Dec 06, 2021 |
|
S6 Ep14: Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology
|
Dec 02, 2021 |
|
S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
|
Nov 29, 2021 |
|
S6 Ep12: Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer
|
Nov 25, 2021 |
|
S6 Ep11: Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
|
Nov 22, 2021 |
|
S6 Ep10: Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
|
Nov 18, 2021 |
|
S6 Ep9: Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
|
Nov 15, 2021 |
|
S6 Ep8: Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer
|
Nov 11, 2021 |
|
S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer
|
Nov 08, 2021 |
|
S6 Ep6: Yarchoan Talks Research Directions in Fibrolamellar Carcinoma
|
Nov 04, 2021 |
|
S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL
|
Nov 01, 2021 |
|
S6 Ep4: Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases
|
Oct 28, 2021 |
|
S6 Ep3: Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
|
Oct 25, 2021 |
|
S6 Ep2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
|
Oct 21, 2021 |
|
S6 Ep1: Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers
|
Oct 18, 2021 |
|
S5 Ep50: Gordan on Growing the Infrastructure for In-House Genomic Testing
|
Oct 14, 2021 |
|
S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
|
Oct 11, 2021 |
|
S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
|
Oct 07, 2021 |
|
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
|
Oct 04, 2021 |
|
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
|
Sep 30, 2021 |
|
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
|
Sep 27, 2021 |
|
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
|
Sep 23, 2021 |
|
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
|
Sep 20, 2021 |
|
S5 Ep42: Neel on Maximizing Research Strides in Oncology
|
Sep 16, 2021 |
|
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
|
Sep 13, 2021 |
|
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
|
Sep 09, 2021 |
|
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
|
Sep 06, 2021 |
|
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
|
Sep 02, 2021 |
|
S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS
|
Aug 30, 2021 |
|
S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
|
Aug 26, 2021 |
|
S5 Ep35: Krie and Yuan Talk Toxicity Management in Breast Cancer
|
Aug 23, 2021 |
|
S5 Ep34: DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19
|
Aug 19, 2021 |
|
S5 Ep33: Chachoua on Leveraging Screening Opportunities in Lung Cancer
|
Aug 16, 2021 |
|
S5 Ep32: Making the Most of Molecular Testing in Breast Cancer
|
Aug 12, 2021 |
|
S5 Ep31: FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
Aug 09, 2021 |
|
S5 Ep30: Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting
|
Aug 05, 2021 |
|
S5 Ep29: Rariy Reviews In-Home Infusion Initiative in Oncology
|
Aug 02, 2021 |
|
S5 Ep28: Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers
|
Jul 29, 2021 |
|
S5 Ep27: Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
|
Jul 26, 2021 |
|
S5 Ep26: FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer
|
Jul 22, 2021 |
|
S5 Ep25: Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
|
Jul 19, 2021 |
|
S5 Ep24: Mayer on the Optimization of SERDs in ER+ Breast Cancer
|
Jul 15, 2021 |
|
S5 Ep23: Wainberg Weighs In on Advances in HER2+ GI Cancers
|
Jul 12, 2021 |
|
S5 Ep22: CTCA Leaders Provide Post-Pandemic Predictions in Oncology
|
Jul 08, 2021 |
|
S5 Ep21: Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers
|
Jul 05, 2021 |
|
S5 Ep20: Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer
|
Jul 01, 2021 |
|
S5 Ep19: Lee-Kim on Fostering a Fulfilling Fellowship in Oncology
|
Jun 28, 2021 |
|
S5 Ep18: Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
|
Jun 24, 2021 |
|
S5 Ep17: Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19
|
Jun 21, 2021 |
|
S5 Ep16: George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline
|
Jun 17, 2021 |
|
S5 Ep15: Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer
|
Jun 14, 2021 |
|
S5 Ep14: Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma
|
Jun 10, 2021 |
|
S5 Ep13: FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
|
Jun 07, 2021 |
|
S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC
|
Jun 03, 2021 |
|
S5 Ep12: Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma
|
May 31, 2021 |
|
S5 Ep11: Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma
|
May 27, 2021 |
|
S5 Ep10: Kaklamani Speaks to a Shifting HER2+ Breast Cancer Paradigm
|
May 24, 2021 |
|
S5 Ep9: UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma
|
May 20, 2021 |
|
S5 Ep8: Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer
|
May 17, 2021 |
|
S5 Ep7: O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer
|
May 13, 2021 |
|
S5 Ep6: Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
|
May 10, 2021 |
|
S5 Ep5: FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma
|
May 06, 2021 |
|
S5 Ep4: FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma
|
May 03, 2021 |
|
S5 Ep3: Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies
|
Apr 29, 2021 |
|
S5 Ep2: FDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCC
|
Apr 26, 2021 |
|
S5 Ep1: Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies
|
Apr 22, 2021 |
|
S4 Ep50: Saba Spotlights the Nuances of Treating Nasopharygeal Cancer
|
Apr 19, 2021 |
|
S4 Ep49: Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium
|
Apr 15, 2021 |
|
S4 Ep48: FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma
|
Apr 12, 2021 |
|
S4 Ep47: FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer
|
Apr 08, 2021 |
|
S4 Ep46: Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research
|
Apr 05, 2021 |
|
S4 Ep45: The Marshalls Open a Candid Conversation About Cancer
|
Apr 01, 2021 |
|
S4 Ep44: Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer
|
Mar 29, 2021 |
|
S4 Ep43: Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer
|
Mar 25, 2021 |
|
S4 Ep42: Borgen Breaks Down the Domino Effect of Expanded Education and Banished Stigmas in Male Breast Cancer
|
Mar 22, 2021 |
|
S4 Ep41: Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer
|
Mar 18, 2021 |
|
S4 Ep40: Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC
|
Mar 16, 2021 |
|
S4 Ep39: Levy Lauds Biomarker-Driven Data in Lung Cancer
|
Mar 11, 2021 |
|
S4 Ep38: FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer
|
Mar 08, 2021 |
|
S4 Ep37: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
|
Mar 04, 2021 |
|
S4 Ep36: FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC
|
Mar 01, 2021 |
|
S4 Ep35: Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
|
Feb 25, 2021 |
|
S4 Ep34: Nichols on Navigating the Nuances of von Hippel-Lindau Disease
|
Feb 22, 2021 |
|
S4 Ep33: Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer
|
Feb 18, 2021 |
|
S4 Ep32: Schilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in Cancer
|
Feb 15, 2021 |
|
S4 Ep31: Klempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid Tumors
|
Feb 11, 2021 |
|
S4 Ep30: Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology
|
Feb 08, 2021 |
|
S4 Ep29: Mesa and Gerds Talk Management Strategies and Emerging Agents in Myelofibrosis
|
Feb 04, 2021 |
|
S4 Ep27: Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC
|
Feb 01, 2021 |
|
S4 Ep28: Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC
|
Feb 01, 2021 |
|
S4 Ep26: Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer
|
Jan 28, 2021 |
|
S4 Ep25: FDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCC
|
Jan 25, 2021 |
|
S4 Ep24: Forecasting Future Advances Across Oncology
|
Jan 21, 2021 |
|
S4 Ep23: Pursuing New Paradigms in Prostate Cancer
|
Jan 14, 2021 |
|
S4 Ep22: Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer
|
Jan 11, 2021 |
|
S4 Ep21: Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma
|
Jan 07, 2021 |
|
S4 Ep20: Spotlighting Management Strategies Across Sarcoma Subtypes
|
Jan 04, 2021 |
|
S4 Ep19: Lindau on Leading Successful Surgical Fellowships
|
Dec 31, 2020 |
|
S4 Ep18: Gaining Insight Into the Management of Gastrointestinal Malignancies
|
Dec 28, 2020 |
|
S4 Ep17: Druker Details a Career of Determination, Patient Impact, and Family Success
|
Dec 24, 2020 |
|
S4 Ep16: Multimodality Therapy Makes Waves in Bladder Cancer
|
Dec 21, 2020 |
|
S4 Ep15: Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC
|
Dec 17, 2020 |
|
S4 Ep14: Learning to Tailor Targeted and Immune Therapy in Lung Cancer
|
Dec 15, 2020 |
|
S4 Ep13: Bardia Brings to Light Complex Breast Cancer Cases
|
Dec 10, 2020 |
|
S4 Ep12: Robert Recaps a Career of Clinical Research in Melanoma
|
Dec 07, 2020 |
|
S4 Ep11: Huntsman Homes in on the Integration of Precision Medicine in Oncology
|
Dec 03, 2020 |
|
S4 Ep10: Marvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic Oncology
|
Nov 30, 2020 |
|
S4 Ep9: Loaiza-Bonilla on Applications, Actionability, and Affordability of AI in Oncology
|
Nov 26, 2020 |
|
S4 Ep8: Oxnard on Opening the Door for Precision Medicine in Lung Cancer
|
Nov 23, 2020 |
|
S4 Ep7: Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
|
Nov 19, 2020 |
|
S4 Ep6: Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era
|
Nov 16, 2020 |
|
S4 Ep5: Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
|
Nov 12, 2020 |
|
S4 Ep4: Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium
|
Nov 09, 2020 |
|
S4 Ep3: Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer
|
Nov 06, 2020 |
|
S4 Ep2: Lyman on Bringing Biosimilars From Bench to Bedside in Oncology
|
Nov 02, 2020 |